Increasing doses of CP-24879 selectively impaired the CFC of MLL-AF9–expressing mouse AML cells but not that of normal mouse hematopoietic stem and progenitor cells (Fig. S5A). This evidence concerns the gene KMT2A and acute myeloid leukemia.